Receptor News and Research

RSS

Corcept receives FDA approval for Korlym to treat endogenous Cushing's syndrome

Today, Korlym (mifepristone) was approved by the U.S. Food and Drug Administration to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing's syndrome.

18 Feb 2012

Study reveals immune mechanism for surveillance over EBV infection

Some 90 percent of people are exposed to the Epstein Barr virus (EBV) at some point in their life. Even though it is quickly cleared from the body, the virus can linger silently for years in small numbers of infected B cells.

18 Feb 2012

New UTA method shows promise against heart disease

University of Texas at Austin researchers have demonstrated a new and more effective method for regrowing blood vessels in the heart and limbs - a research advancement that could have major implications for how we treat heart disease, the leading cause of death in the Western world.

17 Feb 2012

Lab-based treatment reminders may not be effective for CKD patients

Laboratory-based treatment reminders meant to improve physicians' prescribing habits for patients with chronic kidney disease (CKD) may not be effective, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

17 Feb 2012

Researchers test nanoscale carbon clusters for cancer chemotherapy

A mixture of current drugs and carbon nanoparticles shows potential to enhance treatment for head-and-neck cancers, especially when combined with radiation therapy, according to new research by Rice University and the University of Texas MD Anderson Cancer Center.

16 Feb 2012

Study underscores power of real-time cell monitoring to dissect pluridimensionality of GPCR signaling

A research team led by Dr. Michel Bouvier at the Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal in Quebec, used the Roche xCELLigence SP Instrument to measure changes in cell response following ligand stimulation.

From Roche Sequencing and Life Science 16 Feb 2012

UC Cancer Institute to enroll up to 60 patients for AMG 595 phase-1 trial

The UC Cancer Institute is one of three centers internationally approved to test an experimental drug's safety and pharmacokinetics and also assess the clinical benefit against recurrent malignant glioma, an aggressive form of brain cancer.

16 Feb 2012

TFF3 protein plays a more sinister role in breast cancer metastasis

The trefoil factor 3 (TFF3) protein protects and maintains the integrity of the epithelial surface in the normal breast. New research has found that while TFF3 protein expression is higher in well-differentiated low grade tumors and therefore associated with features of a good prognosis, it has a more sinister role in breast cancer invasion and metastasis.

16 Feb 2012

Researchers identify potent regulator of sensitivity to insulin

Researchers at Washington University School of Medicine in St. Louis have identified a potent regulator of sensitivity to insulin, the hormone that controls blood sugar levels. The new findings may help scientists find better treatments for type 2 diabetes, obesity and other health problems caused by the body's inability to properly regulate blood sugar.

16 Feb 2012

DC-SIGN molecule appears to play a role in fighting allergy

Scientists at The University of Nottingham have discovered a new molecule that could offer the hope of new treatments for people allergic to the house dust mite.

15 Feb 2012

New group of compounds may protect brain cells from inflammation

Scientists at Emory University School of Medicine have identified a new group of compounds that may protect brain cells from inflammation linked to seizures and neurodegenerative diseases.

15 Feb 2012

Scientists identify and describe molecular mechanism behind holoprosencephaly

Researchers of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have now identified and described a molecular mechanism underlying the most common malformation of the brain in humans. In holoprosencephaly (HPE), the forebrain (prosencephalon) is only incompletely formed.

14 Feb 2012

Marshall University researcher to understand connections between cancer and obesity

A Marshall University researcher has been awarded a one-year, $60,000 grant from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation.

14 Feb 2012

Researchers pinpoint source of Loeys-Dietz syndrome

A USC research team has pinpointed the source of a genetic disorder that causes life-threatening birth defects, which may allow doctors to quickly diagnose and better treat the disease.

14 Feb 2012

Trevena commences TRV130 Phase I clinical trial for severe post-operative pain

Trevena, Inc., the leader in discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today the initiation of a Phase I clinical trial of TRV130, a novel candidate designed for the intravenous treatment of moderate-to-severe post-operative pain.

13 Feb 2012

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the fourth quarter and full year 2011 and provided an update on development programs.

13 Feb 2012

Researchers discover a connection of peroxisomal protein import and receptor export

The group of Prof. Dr. Ralf Erdmann at the Ruhr-Universit-t Bochum discovered a connection of peroxisomal protein import and receptor export. In the Journal of Biological Chemistry, they disclosed that enzymes only get imported into certain cell organelles (peroxisomes) upon coupling of their import to the recycling of their transport protein.

13 Feb 2012

Incident malignancy four times higher among children with JIA

New research reports that incident malignancy among children with juvenile idiopathic arthritis (JIA) is four times higher than in those without the disease. Findings now available in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR), suggest JIA treatment, such as tumor necrosis factor (TNF) inhibitors, does not necessarily explain the development of cancer in this pediatric population.

13 Feb 2012

Curcumin may block growth of castrate-resistant prostate tumors

Curcumin, an active component of the Indian curry spice turmeric, may help slow down tumor growth in castration-resistant prostate cancer patients on androgen deprivation therapy (ADT), a study from researchers at Jefferson's Kimmel Cancer Center suggests.

13 Feb 2012

Study investigates how cytokine IFN-λ release is regulated

In new research appearing in this month's issue of the journal Nature Immunology, Roy Curtiss, director of the Center for Infectious Diseases and Vaccinology at the Biodesign Institute at Arizona State University, along with international collaborators, investigates the coordination of a particular type of immune response, involving the release of of IFN-λ- a cell-signaling protein molecule known as a cytokine.

10 Feb 2012